GB201912437D0 - CR2 Binding Proteins and their use in Medical Therapy - Google Patents

CR2 Binding Proteins and their use in Medical Therapy

Info

Publication number
GB201912437D0
GB201912437D0 GBGB1912437.9A GB201912437A GB201912437D0 GB 201912437 D0 GB201912437 D0 GB 201912437D0 GB 201912437 A GB201912437 A GB 201912437A GB 201912437 D0 GB201912437 D0 GB 201912437D0
Authority
GB
United Kingdom
Prior art keywords
binding proteins
medical therapy
therapy
medical
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1912437.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Priority to GBGB1912437.9A priority Critical patent/GB201912437D0/en
Publication of GB201912437D0 publication Critical patent/GB201912437D0/en
Priority to AU2020338807A priority patent/AU2020338807A1/en
Priority to KR1020227010200A priority patent/KR20220053000A/ko
Priority to CN202080060956.4A priority patent/CN114375305A/zh
Priority to PCT/EP2020/074049 priority patent/WO2021038023A1/en
Priority to CA3151687A priority patent/CA3151687A1/en
Priority to EP20767985.3A priority patent/EP4021938A1/en
Priority to MX2022002478A priority patent/MX2022002478A/es
Priority to BR112022003623A priority patent/BR112022003623A2/pt
Priority to JP2022513412A priority patent/JP7603061B2/ja
Priority to US17/639,096 priority patent/US20230032643A1/en
Priority to ARP200102433A priority patent/AR119865A1/es
Priority to TW109129646A priority patent/TWI851801B/zh
Priority to IL290649A priority patent/IL290649A/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB1912437.9A 2019-08-30 2019-08-30 CR2 Binding Proteins and their use in Medical Therapy Ceased GB201912437D0 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
GBGB1912437.9A GB201912437D0 (en) 2019-08-30 2019-08-30 CR2 Binding Proteins and their use in Medical Therapy
TW109129646A TWI851801B (zh) 2019-08-30 2020-08-28 Cr2結合蛋白及其於醫藥療法之用途
EP20767985.3A EP4021938A1 (en) 2019-08-30 2020-08-28 Cr2 binding proteins and their use in medical therapy
BR112022003623A BR112022003623A2 (pt) 2019-08-30 2020-08-28 Proteínas de ligação a cr2 e seu uso em terapia médica
CN202080060956.4A CN114375305A (zh) 2019-08-30 2020-08-28 Cr2结合蛋白及其在医学疗法中的用途
PCT/EP2020/074049 WO2021038023A1 (en) 2019-08-30 2020-08-28 Cr2 binding proteins and their use in medical therapy
CA3151687A CA3151687A1 (en) 2019-08-30 2020-08-28 Cr2 binding proteins and their use in medical therapy
AU2020338807A AU2020338807A1 (en) 2019-08-30 2020-08-28 CR2 binding proteins and their use in medical therapy
MX2022002478A MX2022002478A (es) 2019-08-30 2020-08-28 Proteinas de union a cr2 y su uso en tratamientos medicos.
KR1020227010200A KR20220053000A (ko) 2019-08-30 2020-08-28 Cr2 결합 단백질 및 의료 요법에서의 그의 용도
JP2022513412A JP7603061B2 (ja) 2019-08-30 2020-08-28 Ｃｒ２結合タンパク質および医学的治療におけるそれらの使用
US17/639,096 US20230032643A1 (en) 2019-08-30 2020-08-28 CR2 Binding Proteins and their use in Medical Therapy
ARP200102433A AR119865A1 (es) 2019-08-30 2020-08-28 Proteínas de unión a cr2 y su uso en tratamientos médicos
IL290649A IL290649A (en) 2019-08-30 2022-02-15 cr2 binding proteins and their use in medical treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1912437.9A GB201912437D0 (en) 2019-08-30 2019-08-30 CR2 Binding Proteins and their use in Medical Therapy

Publications (1)

Publication Number Publication Date
GB201912437D0 true GB201912437D0 (en) 2019-10-16

Family

ID=68207176

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1912437.9A Ceased GB201912437D0 (en) 2019-08-30 2019-08-30 CR2 Binding Proteins and their use in Medical Therapy

Country Status (14)

Country Link
US (1) US20230032643A1 (enExample)
EP (1) EP4021938A1 (enExample)
JP (1) JP7603061B2 (enExample)
KR (1) KR20220053000A (enExample)
CN (1) CN114375305A (enExample)
AR (1) AR119865A1 (enExample)
AU (1) AU2020338807A1 (enExample)
BR (1) BR112022003623A2 (enExample)
CA (1) CA3151687A1 (enExample)
GB (1) GB201912437D0 (enExample)
IL (1) IL290649A (enExample)
MX (1) MX2022002478A (enExample)
TW (1) TWI851801B (enExample)
WO (1) WO2021038023A1 (enExample)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
EP1001021B1 (en) * 1998-09-25 2003-08-27 Wolfgang Prodinger Monoclonal antibody to human CD21, and its uses
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
JP2004529945A (ja) * 2001-05-17 2004-09-30 ラ ホヤ ファーマシューティカル カンパニー Ｃｄ２１を阻害する薬剤を使用して抗体媒介性病理を処置する方法
AU2003298650B2 (en) * 2002-11-15 2010-03-11 Musc Foundation For Research Development Complement receptor 2 targeted complement modulators
US20050164301A1 (en) 2003-10-24 2005-07-28 Avidia Research Institute LDL receptor class A and EGF domain monomers and multimers
US8961967B2 (en) 2009-11-30 2015-02-24 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
BR112012029067A2 (pt) * 2010-05-14 2019-09-24 Univ Colorado Regents grupos-alvo de receptor do complemento 2 (cr2) melhorados.
WO2016187216A1 (en) * 2015-05-18 2016-11-24 Bluebird Bio, Inc. Anti-ror1 chimeric antigen receptors
WO2017189281A1 (en) * 2016-04-27 2017-11-02 The Regents Of The University Of Michigan C3d cellular and acellular vaccines for the prevention and treatment of cancer

Also Published As

Publication number Publication date
TW202126687A (zh) 2021-07-16
IL290649A (en) 2022-04-01
AU2020338807A1 (en) 2022-03-10
JP7603061B2 (ja) 2024-12-19
AU2020338807A8 (en) 2022-06-02
CN114375305A (zh) 2022-04-19
EP4021938A1 (en) 2022-07-06
JP2022545947A (ja) 2022-11-01
TWI851801B (zh) 2024-08-11
AR119865A1 (es) 2022-01-19
US20230032643A1 (en) 2023-02-02
MX2022002478A (es) 2022-03-22
CA3151687A1 (en) 2021-03-04
KR20220053000A (ko) 2022-04-28
WO2021038023A1 (en) 2021-03-04
BR112022003623A2 (pt) 2022-05-24

Similar Documents

Publication Publication Date Title
IL277343B1 (en) "CD47-binding factors and their uses in the treatment of diseases"
IL320762A (en) Fibrous binders and their use
SG11202103022WA (en) Dll3 binding proteins and methods of use
IL278058A (en) Oligonucleotide compounds of 5-cap-tetranucleotide or higher and their uses in RNA production, protein expression and medicine
IL288610A (en) Recombinant fap binding proteins and their use
IL288403A (en) Viral vectors and their uses for adoptive cell therapy
PT3443006T (pt) Proteínas de ligação triespecíficas e/ou trivalentes
EP3464608A4 (en) THERAPEUTIC RECOMBINANT KLOTHO PROTEINS, COMPOSITIONS AND METHODS THEREFOR
IL284157A (en) Anti-pd-1 binding proteins and methods of using them
EP3946451A4 (en) FIBROBLAST ACTIVATING PROTEIN BINDING AGENTS AND USE THEREOF
ZA202103259B (en) Modified cas9 protein, and use thereof
PL3290441T3 (pl) Białko wiążące RGMa i jego zastosowanie
IL288728A (en) Anti-sortilin antibodies for use in therapy
SG11202104354TA (en) Mini-nucleosome core proteins and use in nucleic acid delivery
SG11202100568WA (en) Il-17a binding peptides and medical uses thereof
GB201905520D0 (en) Compounds and their therapeutic use
SG11202012661WA (en) Immunodominant proteins and fragments in multiple sclerosis
GB201918541D0 (en) Therapeutic compounds and their use
IL279178A (en) Weird Cas9 protein and its use
ES3063303T3 (en) Fibronectin-binding peptides for use in tumor or fibrosis diagnosis and therapy
SG11202105029WA (en) Novel folr1 specific binding proteins for cancer diagnosis and treatment
IL309885A (en) Alpha-surface polypeptides and their use
GB201814040D0 (en) Testing and therapy
IL290649A (en) cr2 binding proteins and their use in medical treatment
IL280564A (en) Selection of therapeutic proteins under simulated conditions in the living body

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)